search
Back to results

Efficacy Trial of 3804-250A in the Prevention of Cold Illnesses

Primary Purpose

Common Cold

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
3804-250A
3804-291
Sponsored by
The Dial Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Common Cold focused on measuring cold, common, rhinovirus

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • healthy normal
  • good general health

Exclusion Criteria:

  • pregnancy
  • insulin dependent diabetes
  • daily smoker
  • skin disease on the hands/wrists
  • immunological disorders
  • occupation involving frequent handwashing
  • common cold symptoms

Sites / Locations

  • TKL Research, Inc.
  • University of Virginia School of Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Placebo

3804-250A

Arm Description

Outcomes

Primary Outcome Measures

The Primary Efficacy Endpoint of This Study is the Incidence of Cold Illnesses.
Comparison of the total number of incidence of cold illnesses over the course of the study per 100 subjects in each treatment group

Secondary Outcome Measures

Rhinovirus Infections.
The incidence of rhinovirus infections
Rhinovirus-associated Colds
The incidence of rhinovirus-associated cold illnesses.

Full Information

First Posted
September 26, 2008
Last Updated
March 21, 2012
Sponsor
The Dial Corporation
Collaborators
Hill Top Research, TKL Research, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00762476
Brief Title
Efficacy Trial of 3804-250A in the Prevention of Cold Illnesses
Official Title
A MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II EFFICACY TRIAL OF AV LOTION (FORMULA NO. 3804-250A) FOR THE PREVENTION OF COLD ILLNESS IN HUMAN SUBJECTS
Study Type
Interventional

2. Study Status

Record Verification Date
March 2012
Overall Recruitment Status
Completed
Study Start Date
August 2008 (undefined)
Primary Completion Date
November 2008 (Actual)
Study Completion Date
November 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The Dial Corporation
Collaborators
Hill Top Research, TKL Research, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the efficacy of 3804-250A in the prevention of the common cold. The study will also evaluate whether 3804-250A prevents rhinovirus infection, a virus that causes many common colds.
Detailed Description
Rhinovirus infections are the most frequent cause up to 80% of cold illnesses during the fall rhinovirus season. While viral upper respiratory infections are generally mild and self-limited, they are associated with an enormous economic burden both in lost productivity and in expenditures for treatment. Rhinovirus infection is frequently associated with medical complications that have substantial morbidity such as acute otitis media and exacerbation of asthma. Marketed treatment options for rhinovirus consist primarily of symptomatic cold remedies have only modest effects on specific cold symptoms. 3804-250A is under investigation for the prevention of rhinovirus infection by interruption of person-to-person transmission appears to be technologically and economically feasible. The study is a randomized, double-blind, Placebo controlled, multi-site, parallel design clinical trial conducted in the natural setting. The study will be conducted during a 10-week period during the fall rhinovirus epidemic season. Healthy, normal subjects will be recruited and randomly assigned to the AV Lotion or Placebo control group. Subjects will use the assigned test product on a defined schedule and will record the presence of cold illness symptoms daily. Subjects will return to the study site every week during the study for review and clarification of study diary entries, for review and assessment of compliance, for specimen collection for rhinovirus PCR.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Common Cold
Keywords
cold, common, rhinovirus

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
411 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Title
3804-250A
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
3804-250A
Intervention Description
topical product apply 2 pumps apply at least every 4 hours or after hand washing
Intervention Type
Drug
Intervention Name(s)
3804-291
Intervention Description
topical apply 2 pumps apply at least every 4 hours or after hand washing
Primary Outcome Measure Information:
Title
The Primary Efficacy Endpoint of This Study is the Incidence of Cold Illnesses.
Description
Comparison of the total number of incidence of cold illnesses over the course of the study per 100 subjects in each treatment group
Time Frame
10 weeks
Secondary Outcome Measure Information:
Title
Rhinovirus Infections.
Description
The incidence of rhinovirus infections
Time Frame
10 weeks
Title
Rhinovirus-associated Colds
Description
The incidence of rhinovirus-associated cold illnesses.
Time Frame
10 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: healthy normal good general health Exclusion Criteria: pregnancy insulin dependent diabetes daily smoker skin disease on the hands/wrists immunological disorders occupation involving frequent handwashing common cold symptoms
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ronald B Turner, MD
Organizational Affiliation
University of Virginia School of Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Michael E Casser, MD
Organizational Affiliation
TKL Research, Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
TKL Research, Inc.
City
Paramus
State/Province
New Jersey
ZIP/Postal Code
07652
Country
United States
Facility Name
University of Virginia School of Medicine
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22908
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Efficacy Trial of 3804-250A in the Prevention of Cold Illnesses

We'll reach out to this number within 24 hrs